Document Type

Article

Publication Date

8-1-2022

Comments

This article is the authors' final version prior to being accepted for publication in Journal of Perinatology. Forthcoming.

Abstract

Objective
To determine if treatment with a 5-HT3 antagonist (ondansetron) reduces need for opioid therapy in infants at risk for neonatal opioid withdrawal syndrome (NOWS).

Study Design
A multicenter, randomized, placebo controlled, double blind clinical trial of ninety (90) infants. The intervention arms were intravenous ondansetron or placebo during labor followed by a daily dose of ondansetron or placebo in infants for five days.

Results
Twenty-two (49%) ondansetron-treated and 26 (63%) placebo-treated infants required pharmacologic treatment (p>0.05). The Finnegan score was lower in the ondansetron-treated group (4.6 vs. 5.6, p=0.02). A non-significant trend was noted for the duration of hospitalization. There was no difference in need for phenobarbital or clonidine therapy, or total dose of morphine in the first 15 days of NOWS treatment.

Conclusions
Ondansetron treatment reduced the severity of NOWS symptoms; and there was an indication that it could reduce the length of stay.

Language

English

Available for download on Friday, March 31, 2023

Share

COinS